Mycoplasma Safety Testing in Pharmaceutical Products
Ensuring the safety of your products, and therefore the safety of patients, is a critical concern for the manufacturers of pharmaceutical products. Contaminated cell cultures and products have the potential to cause serious illness in humans. If discovered before shipment, contamination can create a significant delay in product release and increased production costs. This white paper provides an overview of mycoplasma testing and considerations to address when executing these studies.